Experimental cell combo takes on advanced cancers in early trial
NCT ID NCT07407985
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also checking how long it stays in the body and whether it shows any signs of shrinking tumors. Because this is a Phase 1 study, it is too soon to know if the treatment will work, and the focus is on safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GK01 cell injection combined with a PD-1 monoclonal antibody
- What this could lead to
- If it works, this could point toward a new combination treatment for advanced solid tumors that helps the immune system fight cancer more effectively.
- What could go wrong
- This is a very early Phase 1 trial with only 15 participants, so it is primarily testing safety, not effectiveness. The treatment may not shrink tumors or improve survival, and side effects could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?